Generation of Anaphylatoxins by Human β-Tryptase from C3, C4, and C5

Abstract

Generation of Anaphylatoxins by Human
-Tryptase from C3, C4, and C51 Yoshihiro Fukuoka,* Han-Zhang Xia,* Laura B. Sanchez-Mun˜oz,† Anthony L. Dellinger,* Luis Escribano,† and Lawrence B. Schwartz2* Both mast cells and complement participate in innate and acquired immunity. The current study examines whether
-tryptase, the major protease of human mast cells, can directly generate bioactive complement anaphylatoxins. Important variables included pH, monomeric vs tetrameric forms of
-tryptase, and the
-tryptase-activating polyanion. The B12 mAb was used to stabilize
-tryptase in its monomeric form. C3a and C4a were best generated from C3 and C4, respectively, by monomeric
-tryptase in the presence of low molecular weight dextran sulfate or heparin at acidic pH. High molecular weight polyanions increased degradation of these anaphylatoxins. C5a was optimally generated from C5 at acidic pH by
-tryptase monomers in the presence of high molecular weight dextran sulfate and heparin polyanions, but also was produced by
-tryptase tetramers under these conditions. Mass spectrometry verified that the molecular mass of each anaphylatoxin was correct. Both
-tryptase-generated C5a and C3a (but not C4a) were potent activators of human skin mast cells. These complement anaphylatoxins also could be generated by
-tryptase in releasates of activated skin mast cells. Of further biologic interest,
-tryptase also generated C3a from C3 in human plasma at acidic pH. These results suggest
-tryptase might generate complement anaphylatoxins in vivo at sites of inflammation, such as the airway of active asthma patients where the pH is acidic and where elevated levels of
-tryptase and complement anaphylatoxins are detected. The Journal of Immunology, 2008, 180: 6307–6316. A lthough levels of both C3a and C5a are increased in bronchoalveolar lavage fluid obtained from subjects with asthma (1–4), how they are produced in asthmatic airways is uncertain. Efficient generation of these anaphy

Key Biomarkers

Symptom Clusters